Publication | Closed Access

2-Substituted-4-aryl-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,5]oxazocin-5-one as a structurally new NK1 antagonist

Medicinal ChemistryMedicineMechanism Of ActionPharmacological AgentNew Nk1 AntagonistPharmacotherapyPharmacologyDrug Discovery